Skip to main content
. Author manuscript; available in PMC: 2015 Dec 28.
Published in final edited form as: J Control Release. 2014 Oct 24;0:272–286. doi: 10.1016/j.jconrel.2014.10.016

Fig. 13.

Fig. 13

In vivo antitumor activity of different DOX formulations in 4T1.2 syngeneic mouse model. Solid arrows indicate the i.v. administration. A: relative tumor volume. B: body weight. *p < 0.0005, compared to Doxil. & p < 0.001, compared to PEG5K-VE2/DOX; # p < 0.05, compared to PEG5K-Fmoc-VE2/DOX (10 mg/kg); p < 0.05, compared to PEG5K-VE2/DOX; β p < 0.005, compared to Doxil.